To make things easier, leave this box checked On shared devices, we recommend that you disconnect from Euroquity when you are done
Email

You will receive an email to define a new password

Location

Select your country

and your language

Hi ,

Welcome to your personnel profile page! Fill in your information in order to become more visible to organizations that interest you.

% completed

%

Inflection Biosciences Ltd_media
medal 2
This profile is validated by 2 label.

Company

Inflection Biosciences Ltd

Inflection Biosciences Ltd_logo
37
EQ SCORE

The EQ Score shows the company's activity and appeal on the platform: profile completeness, news, likes, follows, membership in one or more labels or communities, number of members in its network, etc.

Inflection Biosciences pipeline includes first-in-class IBL-202, a dual PIM and PI3K inhibitor in development for B-cell malignancies, the IBL-100s (PIM kinase inhibitors) and AUM302, partnered with AUM Biosciences.

Dublin, Dublin, Ireland

Send a message

English

Inflection Biosciences Ltd

English

Inflection Biosciences Ltd, an award winning biotech ased in Dublin and Boston, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, T-cell lymphoma and leukemia. The IBL-100 series comprises selective pan-PIM kinase...

See more

Inflection Biosciences Ltd, an award winning biotech ased in Dublin and Boston, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). IBL-202 is a first-in-class PIM/PI3K inhibitor with pre-clincial data supporting its potential in B-cell malignancies, T-cell lymphoma and leukemia. The IBL-100 series comprises selective pan-PIM kinase inhibitors with pre-clinical proof of concept in AML and lung cancer. The copmany's partnered pipeline comprises AUM302 is a first-in-class, orally available PIM/PI3K/mTOR inhibitor, partnered with AUM Biosciences, fro which the company wil earn contigent revenue streams. Pre-clincal proof of conept in B-cell malignancies, breast cancer, lung cancer, AML and neuroblastoma has been generated, with results published in peer review journals.  The quality of company's research has been recognised in its receipt of funding from the European Union's Horizon 2020 in 2019. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com

  • 1

    Followers

  • 1

    Like

Our latest news

Our network

Your request has been sent
Join this network
Your message has been sent

Certifications

European Innovation Council - Accelerator beneficiaries
This label is a guarantee for investors to discover selected companies benefiting from Business acceleration services provided by the European Commission.
167 Entities
Seal of Excellence
The Seal of Excellence is a quality label awarded to project proposals submitted to Horizon 2020 which succeeded a highly competitive evaluation process by independent experts, but did not receive funding due to budget limits. This quality label is a guarantee for investors to find high standard project proposals from European SMEs with growth potential.
1481 Entities

Communities

InvestHorizon
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected DEEP TECH companies.
2672 Members
Access2EIC
The Access2EIC -Seal of Excellence community aims at gathering high potential European companies that received from the European Commission a “Seal of Excellence” certificate and European equity investors. https://access2eic.eu/
2140 Members
BlueInvest
1609 Members

Our history

Start in 31/12/2012

  • 31/12/2012

    Inflection Biosciences Ltd incorporated in Dublin, Ireland

  • 28/05/2013

    Cancer pipeline secure via licensing agreement with Spanish National Cancer Research Centre (CNIO)

  • 1/10/2014

    Awarded Start Up of the year at Pharma Awards

  • 28/5/2018

    IBL-202 peer review publication in British Journal of Hematology

  • 1/7/2019

    AUM302 out-licensing to AUM Biosciences, Singapore

to be continued ...